Literature DB >> 7684887

Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy.

T M Nguyen1, G E Morris.   

Abstract

The majority of mutations in Xp21-linked muscular dystrophy (MD) can be identified by PCR or Southern blotting, as deletions or duplications of groups of exons in the dystrophin gene, but it is not always possible to predict how much altered dystrophin, if any, will be produced. Use of exon-specific monoclonal antibodies (mAbs) on muscle biopsies from MD patients can, in principle, provide information on both the amount of altered dystrophin produced and, when dystrophin is present, the nature of the genetic deletion or point mutation. For this purpose, mAbs which recognize regions of dystrophin encoded by known exons and whose binding is unaffected by the absence of adjacent exons are required. To map mAbs to specific exons, random "libraries" of expressed dystrophin fragments were created by cloning DNAseI digestion fragments of a 4.3-kb dystrophin cDNA into a pTEX expression vector. The libraries were then used to locate the epitopes recognized by 48 mAbs to fragments of 25-60 amino acids within the 1,434-amino-acid dystrophin fragment used to produce the antibodies. This is sufficiently detailed to allow further refinement by using synthetic peptides and, in many cases, to identify the exon in the DMD (Duchenne MD) gene which encodes the epitope. To illustrate their use in dystrophin analysis, a Duchenne patient with a frameshift deletion of exons 42 and 43 makes a truncated dystrophin encoded by exons 1-41, and we now show that this can be detected in the sarcolemma by mAbs up to and including those specific for exon 41 epitopes but not by mAbs specific for exon 43 or later epitopes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684887      PMCID: PMC1682265     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  35 in total

1.  Preferential deletion of exons in Duchenne and Becker muscular dystrophies.

Authors:  S M Forrest; G S Cross; A Speer; D Gardner-Medwin; J Burn; K E Davies
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

2.  Point mutation in the human dystrophin gene: identification through western blot analysis.

Authors:  D E Bulman; S B Gangopadhyay; K G Bebchuck; R G Worton; P N Ray
Journal:  Genomics       Date:  1991-06       Impact factor: 5.736

3.  pUEX, a bacterial expression vector related to pEX with universal host specificity.

Authors:  G M Bressan; K K Stanley
Journal:  Nucleic Acids Res       Date:  1987-12-10       Impact factor: 16.971

4.  Duchenne muscular dystrophy gene product is not identical in muscle and brain.

Authors:  U Nudel; D Zuk; P Einat; E Zeelon; Z Levy; S Neuman; D Yaffe
Journal:  Nature       Date:  1989-01-05       Impact factor: 49.962

5.  Efficient construction of cDNA libraries in plasmid expression vectors using an adaptor strategy.

Authors:  H Haymerle; J Herz; G M Bressan; R Frank; K K Stanley
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

6.  Patterns of exon deletions in Duchenne and Becker muscular dystrophy.

Authors:  A P Read; R C Mountford; S M Forrest; S J Kenwrick; K E Davies; R Harris
Journal:  Hum Genet       Date:  1988-10       Impact factor: 4.132

7.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

Authors:  M Koenig; A P Monaco; L M Kunkel
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

8.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

9.  Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells.

Authors:  D J Blake; D R Love; J Tinsley; G E Morris; H Turley; K Gatter; G Dickson; Y H Edwards; K E Davies
Journal:  Hum Mol Genet       Date:  1992-05       Impact factor: 6.150

10.  Topological mapping of complement component C9 by recombinant DNA techniques suggests a novel mechanism for its insertion into target membranes.

Authors:  K K Stanley; J Herz
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  13 in total

1.  Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.

Authors:  Courtney S Young; Ekaterina Mokhonova; Marbella Quinonez; April D Pyle; Melissa J Spencer
Journal:  J Neuromuscul Dis       Date:  2017

2.  Specificity and VH sequence of two monoclonal antibodies against the N-terminus of dystrophin.

Authors:  G E Morris; C Nguyen
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

3.  Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells.

Authors:  A Fassati; D J Wells; P A Sgro Serpente; F S Walsh; S C Brown; P N Strong; G Dickson
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

4.  Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Michael T Howard; Jacinda B Sampson; Kathryn J Swoboda; Mark B Bromberg; Jerry R Mendell; Laura E Taylor; Christine B Anderson; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Brenda Wong; Richard S Finkel; Carsten G Bonnemann; John W Day; Craig McDonald; Robert B Weiss
Journal:  Hum Mutat       Date:  2011-03       Impact factor: 4.878

5.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

6.  Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.

Authors:  Emanuela Gussoni; Richard R Bennett; Kristina R Muskiewicz; Todd Meyerrose; Jan A Nolta; Irene Gilgoff; James Stein; Yiu-Mo Chan; Hart G Lidov; Carsten G Bönnemann; Arpad Von Moers; Glenn E Morris; Johan T Den Dunnen; Jeffrey S Chamberlain; Louis M Kunkel; Kenneth Weinberg
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin.

Authors:  L T Thanh; T M Nguyen; T R Helliwell; G E Morris
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

8.  Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins.

Authors:  Eric K Johnson; Liwen Zhang; Marvin E Adams; Alistair Phillips; Michael A Freitas; Stanley C Froehner; Kari B Green-Church; Federica Montanaro
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

9.  Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion.

Authors:  Q L Lu; G E Morris; S D Wilton; T Ly; O V Artem'yeva; P Strong; T A Partridge
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

10.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.